Welcome to our dedicated page for Orasure Tech SEC filings (Ticker: OSUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OraSure Technologies, Inc. (NASDAQ: OSUR) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-powered summaries to help interpret complex documents. As a public medical devices issuer, OraSure files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe its financial condition, operating performance, and significant corporate events.
Recent Form 8-K filings referenced by the company include reports of quarterly financial results and related investor communications. For example, OraSure has furnished press releases announcing consolidated financial results for quarters ended June 30 and September 30, along with investor presentations and details of webcast conference calls with analysts and investors. Other 8-K filings document changes in the composition of the board of directors, such as the resignation of a board chair, the appointment of a new chair, and the addition of an independent director, including information about committee assignments and director compensation under the company’s non-employee director compensation policy.
Through its periodic reports, OraSure provides segment and category-level revenue information across diagnostics, sample management solutions, COVID-19 diagnostics, risk assessment testing, molecular services, and non-product and services revenues. These filings also discuss operating expenses, cash and cash equivalents, capital expenditures, and other financial metrics, as well as risk factors and forward-looking statements related to regulatory approvals, customer demand, competition, funding for public health programs, and broader economic conditions.
On this page, Stock Titan’s tools surface real-time updates from EDGAR and apply AI-generated highlights to key sections of OraSure’s filings, helping users quickly identify items such as quarterly performance trends, changes in governance, and material events disclosed in 8-Ks. Users can also review information related to equity awards and director compensation as described in proxy statements and referenced in current reports. Together, these resources offer a structured view of OSUR’s regulatory history and ongoing disclosure obligations.
OraSure Technologies Chief Financial Officer Kenneth J. McGrath reported a Form 4 disclosing a tax-withholding disposition tied to the vesting of restricted stock. On 08/08/2025 the filing shows 12,524 shares were withheld to satisfy tax obligations at a reported price of $2.78 per share. After the withholding he beneficially owned 448,463 shares directly.
The filing is a routine Section 16 disclosure related to compensation vesting rather than an open-market sale. The explanation on the form explicitly states the shares were withheld to pay the tax liability associated with vested restricted shares, indicating this transaction reflects tax withholding on compensation.
OraSure Technologies (OSUR) – Form 4 filing, 07/31/2025: Director Robert W. McMahon satisfied tax withholding on recently vested restricted stock by having 7,317 common shares withheld by the company at an implied price of $3.205 per share (Transaction Code F). Following the transaction, McMahon continues to hold 99,919 shares directly. No derivative securities were reported.
Code F denotes a non-open-market disposition strictly for tax obligations; therefore, it does not represent an active sale decision and has minimal signalling value. The remaining stake indicates continued alignment with shareholders. No other transactions, options, or changes in beneficial ownership were disclosed.